Novo Nordisk's Combo Drug CagriSema Shows 16% Weight Reduction In Second Phase 3 Trial
On Monday, Novo Nordisk A/S NVO announced headline results from the REDEFINE 2 phase 3 trial in the global REDEFINE program.
Novo Nordisk: CagriSema Disappoints Again
Novo Nordisk: CagriSema Disappoints Again
Why Novo Nordisk Stock Is Falling Today
Shares of Novo Nordisk (NVO -8.70%) are tumbling on Monday. The company's stock lost 8.9% as of 10:10 a.m.
Novo Nordisk shares fall on weight-loss drug trial
Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.
Novo Nordisk shares fall on weight loss drug trial results
Novo Nordisk (NYSE:NVO) shares moved lower after the Danish drugmaker unveiled the latest trial results for its weight loss drug CagriSema. The Phase 3 trial, called Redefine 2, showed that CagriSema helped obese or overweight adults with type 2 diabetes reduce their weight by 15.7% after 68 weeks, compared to 3.1% with placebo.
NVO Weight Loss Drug Disappoints, RDFN Acquisition, Airline Price Targets Slashed
Market weakness continued this morning, including in international companies like Novo Nordisk (NVO). Its next-gen weight loss drug trial results weren't enough to draw investors in.
Novo Nordisk Shares Sink on Latest CagriSema Weight Loss Drug Study
Novo Nordisk's (NVO) U.S.-listed shares fell Monday morning following the release of data for a new phase 3 clinical trial of its in-development weight loss drug CagriSema.
Novo Nordisk shares slide 6% after weight loss drug trial disappoints
Novo Nordisk shares declined on Monday after the company reported that its next-generation weight-loss drug, CagriSema, helped obese or overweight adult patients with type 2 diabetes reduce their weight by 15.7% after 68 weeks. The stock dropped around 6.5% in Copenhagen, marking its biggest intraday decline since December 20.
Novo Nordisk shares fall 5.5% after latest trial results for its next-generation weight loss drug
Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.
Novo Nordisk says trial with next-gen drug in diabetics shows 15.7% weight loss
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks.
Novo Nordisk (NVO) Stock Dips While Market Gains: Key Facts
The latest trading day saw Novo Nordisk (NVO) settling at $87.17, representing a -0.99% change from its previous close.
Final Trade: GOOGL, NVO, GDX, MP
The final trades of the day with CNBC's Melissa Lee and the Fast Money traders.
